Annals of Oncology Advance Access published online on April 10, 2007
Annals of Oncology, doi:10.1093/annonc/mdm085
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer
1 Department of Oncology/Hematology
2 Department of Pathology
3 Department of Internal Medicine and Biochemistry
4 Department of the Advanced Medical Technology Center for Diagnosis and Prediction
5 Department of Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea
* Correspondence to: Dr J. G. Kim, Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, 50 Samduck 2-Ga, Jung-Gu, Daegu 700-712, South Korea. Tel: +82-53-420-6522; Fax: +82-53-426-2046; E-mail: jkk21c{at}mail.knu.ac.kr
Background: The present study analyzed vascular endothelial growth factor (VEGF) gene polymorphisms and their impact on the prognosis for patients with gastric cancer.
Patients and methods: Five hundred and three consecutive patients with surgically resected gastric adenocarcinoma were enrolled in the present study. The genomic DNA was extracted from paraffin-embedded tissue and four VEGF (–460T > C, –116G > A, +405G > C, and +936C > T) gene polymorphisms were determined using a polymerase chain reaction-restriction fragment length polymorphism assay.
Results: The survival analysis showed no association of three VEGF gene polymorphisms with the prognosis. For the +936C > T polymorphism, the T/T genotype, however, had a worse overall survival (OS) compared with the C/C genotype (P = 0.037). The –460 T/C or C/C genotype was a poor prognostic factor in patients with stage 0 or I gastric cancer (OS: hazard ratio (HR) = 3.96, disease-free survival (DFS): HR = 4.87). In the haplotype analysis, the CACC haplotype was associated with a significantly worse survival when compared with the TGGC haplotype (OS: HR = 1.72, DFS: HR = 1.73).
Conclusions: VEGF gene polymorphisms were found to be an independent prognostic marker for patients with gastric cancer. Consequently, the analysis of VEGF gene polymorphisms can help identify patient subgroups at high risk of a poor disease outcome.
gastric cancer, gene, polymorphism, prognosis, VEGF
Received for publication October 24, 2006. Revision received December 23, 2006. Accepted for publication February 8, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Hussein, E. Askar, M. Elsaeid, and F. Schaefer Functional polymorphisms in transforming growth factor-beta-1 (TGF{beta}-1) and vascular endothelial growth factor (VEGF) genes modify risk of renal parenchymal scarring following childhood urinary tract infection Nephrol. Dial. Transplant., October 26, 2009; (2009) gfp532v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Schneider, M. Radovich, and K. D. Miller The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer Clin. Cancer Res., September 1, 2009; 15(17): 5297 - 5302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Bradbury, R. Zhai, C. Ma, W. Xu, J. Hopkins, M. J. Kulke, K. Asomaning, Z. Wang, L. Su, R. S. Heist, et al. Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis Clin. Cancer Res., July 15, 2009; 15(14): 4680 - 4685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Park, W.-K. Lee, D.-K. Jung, J.-E. Choi, T.-I. Park, E.-B. Lee, S. Cho, J.-Y. Park, S.-I. Cha, C.-H. Kim, et al. Polymorphisms in the FAS and FASL Genes and Survival of Early Stage Non-small Cell Lung Cancer Clin. Cancer Res., March 1, 2009; 15(5): 1794 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. TAHARA, T. ARISAWA, T. SHIBATA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, M. OKUBO, N. MARUYAMA, T. KAMANO, Y. KAMIYA, et al. Effect of Polymorphisms in the 3'-Untranslated Region (3'-UTR) of VEGF Gene on Gastric Pre-malignant Condition Anticancer Res, February 1, 2009; 29(2): 485 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhai, G. Liu, K. Asomaning, L. Su, M. H. Kulke, R. S. Heist, N. S. Nishioka, T. J. Lynch, J. C. Wain, X. Lin, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk Carcinogenesis, December 1, 2008; 29(12): 2330 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Schultheis, G. Lurje, K. E. Rhodes, W. Zhang, D. Yang, A. A. Garcia, R. Morgan, D. Gandara, S. Scudder, A. Oza, et al. Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab Clin. Cancer Res., November 15, 2008; 14(22): 7554 - 7563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Schneider, M. Wang, M. Radovich, G. W. Sledge, S. Badve, A. Thor, D. A. Flockhart, B. Hancock, N. Davidson, J. Gralow, et al. Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100 J. Clin. Oncol., October 1, 2008; 26(28): 4672 - 4678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lurje, W. Zhang, A. M. Schultheis, D. Yang, S. Groshen, A. E. Hendifar, H. Husain, M. A. Gordon, F. Nagashima, H. M. Chang, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer Ann. Onc., October 1, 2008; 19(10): 1734 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Kim, Y. S. Chae, S. K. Sohn, Y. Y. Cho, J. H. Moon, J. Y. Park, S. W. Jeon, I. T. Lee, G. S. Choi, and S.-H. Jun Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer Clin. Cancer Res., January 1, 2008; 14(1): 62 - 66. [Abstract] [Full Text] [PDF]
|
|